Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Moonshot Energy: From Aspiration to Reality

    Discover how moonshot technologies, such as fusion and advanced geothermal, could reshape global energy, and see why energy stability, secure supply chains, and smart investments are the keys to unlocking this future.

    Read more

  • The Growing Importance of AI in the Revenue Cycle Management Marketplace

    William Blair’s group head of healthcare technology and services analyst, Ryan Daniels, explores how artificial intelligence is revolutionizing healthcare revenue cycle management by automating financial workflows, reducing costs, and reshaping the industry’s future for providers and vendors.

    Listen to the podcast

  • Atlantic Pipe Services Has Been Acquired by Eagle Merchant Partners

    William Blair acted as the exclusive financial advisor to Atlantic Pipe Services in connection with its sale to Eagle Merchant Partners.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures